GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTK) was the recipient of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 165,864 shares, a decline of 93.5% from the July 30th total of 2,555,155 shares. Based on an average daily volume of 7,214,843 shares, the days-to-cover ratio is presently 0.0 days. Approximately 2.3% of the shares of the company are sold short.

GlucoTrack Stock Performance

Shares of GlucoTrack stock traded up $0.01 during trading on Tuesday, reaching $0.34. The company’s stock had a trading volume of 558,349 shares, compared to its average volume of 25,615,654. The business’s 50-day moving average price is $0.39 and its 200-day moving average price is $0.77. The firm has a market cap of $2.63 million, a PE ratio of -0.04 and a beta of 0.70. GlucoTrack has a 52 week low of $0.25 and a 52 week high of $14.14. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.08.

GlucoTrack (NASDAQ:GCTK) last released its quarterly earnings results on Friday, August 14th. The company reported $0.76 EPS for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GCTK. Ikarian Capital LLC bought a new position in shares of GlucoTrack during the fourth quarter worth approximately $177,000. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack in the fourth quarter valued at approximately $52,000. Finally, Bank of America Corp DE boosted its stake in shares of GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after buying an additional 4,085 shares during the period. Institutional investors and hedge funds own 10.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on GCTK. Wall Street Zen raised shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, GlucoTrack has an average rating of “Sell”.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.